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Abstract
Objective. To summarize the evidence in the literature about rehabilitative treatments 
that reduce low anterior resection syndrome (LARS) symptoms in patients who under-
went surgery for colorectal cancer.
Methods. We have search in PubMed, Cochrane Central Register of Controlled Trials, 
Cumulative Index of Nursing and Allied Health and Scopus databases. Studies selected 
were limited to those including only patient undergone low rectal resection with sphinc-
ter preservation and with pre-post assessment with a LARS score. Five articles fit the 
criteria.
Results. The percutaneous tibial nerve stimulation demonstrated moderate results and 
sacral nerve stimulation was found to be the best treatment with greater symptom im-
provement. Only one study considered sexual and urinary problems in the outcomes 
assessment. 
Conclusions. In clinical practice patients should evaluate with the LARS and other score 
for evaluation of urinary and sexual problems. Future research must be implemented 
with higher quality studies to identify the least invasive and most effective treatment/s.
INTRODUCTION
Colorectal cancer is the third most common cancer 
worldwide [1]. Although surgical treatment has im-
proved in recent years, patients who have a sphincter-
preserving operation may experience symptoms that 
can affect their quality of life (QOL) [2-4]. Eighty per-
cent of patients who undergo a low or very low anterior 
rectal resection will experience fecal or flatus urgency 
or incontinence, frequent bowel movements, bowel 
fragmentation, difficulties emptying, incomplete evacu-
ation, and increased gas postoperatively [2]. This suite 
of symptoms is referred to as low anterior resection syn-
drome (LARS) [2, 3]. Anatomical, nervous/sensory, and 
muscular changes [2-4], the new sphincter’s functional 
capacity [5], pelvic floor functionality [4], colon motili-
ty [6], post-prandial response [7], and the new rectum’s 
compliance [8] are involved in LARS.
Although LARS has been recognized for years, a rig-
orous scientific definition of this syndrome never has 
been developed. Conventionally, it is defined as a bowel 
disorder following rectal resection that affects patient 
QOL [4]. After surgical treatment of a colorectal can-
cer, LARS appears immediately, becomes more evident 
in the first several months, and stabilizes after approxi-
mately one to two years [7].
The incidence of LARS in Europe is approximately 
52% in patients with low rectal surgical treatment [9] 
and the approach to treat it is conservative, consist-
ing of an appropriate diet, fiber intake, mass-forming 
agents [10] and enemas [11]. Nonetheless, LARS has 
adverse effects on patient satisfaction and QOL. The 
literature demonstrates the availability of different re-
habilitation treatments [10, 12, 13-15], but currently 
there is no evidence of the best rehabilitative interven-
tion to improve LARS patients’ symptoms. 
Therefore, the goal of this paper was to summarize 
the evidence available in the literature on different re-
habilitative treatments to reduce LARS symptoms in 
patients who have undergone surgery for colorectal 
cancer.
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METHODOLOGY
Study design 
A systematic literature review was conducted accord-
ing to Lefebvre et al. (2013) [16] and Liberati et al. 
(2009) [17] methodologies.
Literature search strategy 
To identify relevant studies, we searched the follow-
ing databases: Pubmed, Cochrane Central Register of 
Controlled Trials (CCTR), Cumulative Index of Nurs-
ing and Allied Health (CINAHL), and Scopus. The 
PICOS (Participants, Interventions, Comparisons, 
Outcomes, and Study Design), respectively: patients 
who underwent low or very low anterior rectal resection 
for rectal neoplasm (P), were treated with rehabilita-
tion therapy (I) by comparison to standard care (C), 
and had fecal incontinence or bowel dysfunctions that 
compromise their quality of life (O). The study designs 
considered were randomized clinical trials and cohort 
studies. Search terms were “low anterior resection syn-
drome,” “rectal neoplasms,” “rectal cancer,” “rehabili-
tation,” “therapy,” “treatments,” “process assessment,” 
“biofeedback,” “electrical stimulation,” “disability eval-
uation,” “early intervention,” “rehabilitation nursing,” 
“fecal incontinence,” “quality of life,” “bowel dysfunc-
tion,” and “outcome.” The MESH terms were com-
bined with free terms and Boolean operators (AND, 
OR) to include all possible combinations. Thereafter, 
a manual search was conducted using a snowball sam-
pling technique [17].
The primary end-points of this systematic review were 
LARS score and QOL. Secondary end-points were anal 
pressure and urinary and sexual symptoms.
Inclusion and exclusion criteria
Studies included were those published through Oc-
tober 2018 that had abstracts available and included 
only adult patients (>18 years) who had undergone low 
rectal resection with sphincter preservation. As a large 
proportion of the elderly public, particularly in the 50 
to 79 years age group, exhibits major LARS in the ab-
sence of any surgical procedure, only studies with pre-
post treatment assessment with a LARS [18] score to 
identify patient with LARS were included. 
Data extraction and risk of bias
Two researchers evaluated the studies independently. 
In the first phase, titles, abstracts, and full texts were 
analyzed to establish the studies’ relevance to the re-
search questions; the risk of bias was assessed using 
the Edward Score [19] for observational studies. The 11 
items of the assessment tool are as follows: definition 
of aims; sample formation; description of inclusion and 
exclusion criteria; description of subject characteristics; 
power calculation; objectivity of outcome measures 
used; adequacy of follow-up; adequacy of analysis (in-
tention to treat); adjustment for baseline differences be-
tween groups; appropriate unit of allocation to groups; 
randomization method. Each item is scored from 0 to 
2 for adequacy and a high score indicates a study’s high 
methodological quality. The total score possible ranges 
from 0 to 22 for experimental studies or from 0 to 16 
for observational studies. In the second phase, the re-
searchers combined the data and resolved any discrep-
ancies by consensus.
RESULTS
Search results
We selected 439 articles, 186 of which were dupli-
cates. Three researchers analyzed the remaining 254 
studies independently and 5 articles that fit the criteria 
were selected (Figure 1).
Additional records
identified through
other sources (n = 12)
Full texts assessed
for eligibility (n = 18)
Records screened at title
and abstract level (n = 241)
Studies included in qualitative
synthesis (n = 5)
Records after duplicates
removed (n = 253)
Records identified through databases searching:
PubMed (n = 223), CINAHL (n = 80),
Cochrane (n=5), Scopus (n = 119)
Full text excluded because
non responded to the
limitation criteria (n = 25)
Records excluded at title and
abstract level (n = 223)
Figure 1
PRISMA Flow Diagram.
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Risk of bias in the studies
The description of the studies’ quality assessment and 
risk of bias are provided in Table 1. The cohort studies 
included demonstrated a low quality in selection crite-
ria [20-24], and no study included a statistical power 
analysis [20-24]. 
Interventions to reduce LARS symptoms
Table 2 provides a summary of the studies’ character-
istics. The rehabilitative treatments used in the studies 
included sacral nerve stimulation (SNS) [20-22] and 
percutaneous tibial nerve stimulation (PTNS) [23, 24]. 
Sacral nerve stimulation intervention
Three studies addressed SNS [20-22] with a total of 
43 participants; one was [21] prospective and the oth-
ers [20-22] retrospective. Patients included had under-
gone a surgical procedure for rectal cancer [20, 21] and 
Table 1
Methodological quality of included studies
Altomare 
et al. 2017 
[23]
D’Hondt 
et al. 2017 
[21]
Eftaiha  
et al. 2017 
[20]
Mege  
et al. 2017 
[22]
Vigorita  
et al. 2017 
[24]
1. Aims/
outcomes
2: explicitly described in article 2 2 2 2 2
1: implied in article
0: unclear
2. Sample 
formation
2: random 1 1 0 1 1
1: quasi-random, sequential series, or total 
available
0: selected, historical, other
3. Inclusion/
exclusion
2: criteria clearly described 2 2 2 0 2
1: implied by patient characteristics, setting
0: unclear
4. Sample 
characteristics
2: three or four characteristics 2 2 2 2 2
1: one or two characteristics
0: no characteristics
5. Power of 
study calculated
2: yes, appropriate 0 0 0 0 0
1: yes, inappropriate
0: no
6. Outcome 
measures
2: objective or validated scale 2 2 2 2 2
1: subjective/self-report
0: not explicit
7. Follow-up 2: >90% of patients enrolled/approached 2 2 2 2 2
1: 80%-90% of patients
0: <80% of patients/no information
8. Analysis 2: intention to treat/including all available data 2 2 2 2 2
1: excluding dropouts but evidence of bias 
adjusted or no bias evident
0: excluding dropouts and no attention to bias
Total score (0-16) for observational studies 13/16 13/16 12/16 11/16 13/16
9. Baseline 
differences
2: none or adjusted
1: differences unadjusted
0: no information
10. Unit of 
allocation
2: appropriate
1: nearly
0: inappropriate
11. 
Randomization
2: random and concealed
1: random but not concealed
0: randomization before protocol exclusions, or 
no information
Total score (0-22) for experimental studies
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other diseases, such as ulcerative recto-colitis [22].
Patients underwent low resection rectum (LAR) [20-
22] with laparoscopic [20, 21] and laparotomic [22] ap-
proaches, and received different treatments, including 
chemotherapy [20, 21], and/or radiotherapy [22]. The 
authors included patients unresponsive to conserva-
tive therapy, such as diarrheal drugs [20-22], diet [20], 
biofeedback (BF) [20], pelvic floor muscle exercises 
(PFME) [21], or PFME and BF combined [22].
With respect to the outcome assessment [20-22], ev-
Table 2 
Data extraction of included studies
Author, year 
of publication, 
country
Aim Study design Sample Instrument Intervention/
description
Results 
Altomare et al. 
2017 [23]
Italy and Spain
To test 
effectiveness of 
PTNS in FI and UI 
in LARS.
Prospective 
Follow up: 6 
months 
Method: convenience
N: 21
Age: average 66 ± 5.8 
years
Gender: M 47.6% 
(10/21), F 52.4% (11/21) 
Inclusion criteria: 
postoperative after 
rectal cancer free 
from anastomotic 
complications, age over 
18 years, LARS score 
≥ 20, LARS duration 
for at least 12 months, 
failure of conservative 
therapy (diet, medical 
treatments and BF) 
Surgical procedure: LAR 
in laparotomy 71.4% 
(15/21), 28.6% (6/21) 
laparoscopy 
Temporary stoma: 66.6% 
(14/21)
Anastomosis type: 
28.5% (6/21) EtE, 71.5% 
(15/21) StE 
Perioperative treatment: 
preoperative 47,6% 
(10/21), postoperative 
61,9% (13/21) CT 
LARS score 
(Emmertsen and 
Laurberg 2012)
TAPE score (Altomare 
et al. 2017) 
FIQL (Rockwood et 
al. 2000)
St Marks score 
(Vaizey et al. 1999) 
ODS score (Altomare 
et al. 2008).
ICIQ-SF score (Tubaro 
et al. 2006).
IUGA-Revised 
(PISQIR) (Rogers et al. 
2013) for woman
IIEF-5 Questionnaire 
(SHIM) (Rosen et al. 
1999) and PEDT score 
(Symond et al. 2007) 
for man 
Baden-Walker score 
for genital prolapse 
(Baden and Walker 
1972)
Urinary retention 
Anorectal 
manometry
PTNS
(12 sessions - 2 
per week for the 
first 4 weeks, and 
1 per week for the 
last 4 weeks - of 30 
minutes. Stimulation 
parameters were set 
at 200 μs pulse width 
and 20 Hz frequency. 
Stimulation was 
gradually increased 
until sensory and/
or motor response 
were seen and set 
at a well-tolerated 
intensity)
The median LARS-score 
significantly decreased 
from 32 (IQ ranges 30-38) 
to 27 (IQ ranges 17- 37, 
p=0.009)
The TAPE-score signifi-
cantly improved from a 
median value of 55 (IQ 
ranges 49- 64.6) to 58 (IQ 
ranges 51-70, p=0.004). 
43% (9/21) of patients 
reported a significant 
(>50%) improvement 
in the St Marks faecal 
incontinence score 
50% (3/6) of patients 
showed an improvement 
in ICIQ-SF for the urinary 
incontinence score 
The ODS score only 
improved significantly 
(>50%) in 3 of the 21 
cases and its median 
value was 9.5 (IQ ranges 
7-14) before and 8.5 (IQ 
ranges 4.7-10.7) after 
PTNS (p= 0.05)
Urinary retention was 
absent in all patients 
and no female patients 
complained of genital 
prolapse 
All the male patients 
except two and all the 
eleven women were not 
sexually active before 
and after treatment. 
Therefore, no changes 
were observed concern-
ing sexual activity after 
PTNS 
The median FIQL score 
at 6 months follow-up 
however, did not show 
significant changes in 
any domain (lifestyle 2.7 
vs 2.8, p=0.468, coping 
1.6 vs 1.4 p=0.808, 
depression 1.7 vs 1.9 
p=0.56, embarrassment 1 
vs 1.3 p=0.27).
The median resting and 
squeezing anal pressures 
did not change signifi-
cantly before and after 
PTNS (33 (range 8-52) vs 
35 (range 10-66) mmHg 
for resting pressure, and 
49 (range 32-124) vs 46 
(range 34-125) mmHg for 
squeeze pressure. Recto 
anal inhibitory reflex was 
present in 5 patients
Drop out: none
Continues 
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ery study used the Cleveland Clinic Florida Fecal In-
continence (CCF-FI) [25], while diaries [20] for bowel 
habit assessment and the fecal incontinence quality of 
life score (FIQL) [26] were used for the QOL assess-
ment [22]. 
The longest follow-up was 19 months (range 4-42) 
[20] and the shortest 9 (1-13) [21]. The outcomes 
demonstrated a statistically significant improvement in 
LARS syndrome [20-22], fecal incontinence (FI), and 
QOL [22]. 
Percutaneous tibial nerve stimulation 
Two prospective studies [23, 24] that included 31 pa-
tients addressed PTNS to assess its efficacy in improv-
ing LARS, QOL, fecal and urinary incontinence, sexual 
dysfunction, and obstructed defecation. Patients under-
went perioperative chemotherapy [23] or preoperative 
chemotherapy combined with postoperative radiother-
apy [24]. In each study [23, 24], patients were included 
after conservative therapy failed (diet, drug, and BF). 
Two studies [23, 34] used FIQL [26] to assess QOL; 
Table 2 
Continued
Author, year 
of publication, 
country
Aim Study design Sample Instrument Intervention/
description
Results 
D’Hondt et al. 
2017 [21]
Belgium 
To investigate 
the impact 
of SNS on all  
symptoms of 
LARS
Prospective 
Follow up: 9 
months (1-13)
Method: convenience
N: 15 
Age: average: 77.66 
Gender: M 73.3% 
(11/15), F 26.7% (4/15)
Inclusion criteria: 
surgical treatment 
for rectal cancer with 
LARS, unresponsive to 
conservative therapy 
(such as ant diarrheal 
drugs and pelvic floor 
physiotherapy).
Surgical procedure: 
LAR 100% with TME 
86.6% (13/15) and 
with PME 13.4% (2/15); 
in laparotomy 53.3% 
(8/15), in laparoscopy 
46.7% (7/15) 
Temporary stoma: 26.7% 
(10/15)
Anastomosis type: EtE 
26,6% (4/15) StE 20% 
(3/15) and JP 53.4% 
(8/15) 
Perioperative 
treatment: preoperative 
80% (12/15) and 
postoperative CT 86.6%  
(13/15)
LARS score 
(Emmertsen and 
Laurberg 2012).
CCF-FI (Jorge and 
Wexner 1993).
Manometry, colpo-
cysto-defecography, 
ultrasound of the 
anal sphincter
SNS
(First, the efficacy of 
the neurostimulation 
for the patient was 
verified through 
percutaneous nerve 
evaluation (PNE). The 
lead was introduced 
through the third 
sacral foramen and 
tested for 2 weeks)
The mean Wexner scores 
decreased from 17.7 to 
4.6 (Z=2.93; p=0.003)
The mean LARS score 
dropped from 36.9 to 
11.4 (Z=2.93; p=0.003) 
Drop out: 4/15
Four patients, all 
with major LARS, had 
insufficient response to 
the PNE procedure
Eftaiha et al.  
2017 [20]
Canada and 
USA
To test the 
efficacy of SNS in 
LARS.
Retrospective 
Follow up:19.5 
months (4-42) 
Method: convenience
N: 12 
Age: average 67.8 ± 10.8
Gender: M 50% (6/12), F 
50% (6/12) 
Inclusion criteria: 
surgical treatment of 
rectal cancer, with LARS, 
unresponsive to BF, fiber, 
anti-mobility agents for 
at least 12 months
Surgical procedure: LAR 
in laparotomy 71.4% 
(15/21) and laparoscopy 
28.6% (6/21) 
Temporary stoma:  ND
Anastomosis type: CA 
58.3% (7/12) and CR 
41.7% (5/12) 
Peri operative 
treatment: preparative 
CT 19% (4/21)
LARS score 
(Emmertsen and 
Laurberg 2012)
CCF-FI (Jorge and 
Wexner 1993)
Bowel diary
 
Anal manometry, 
endo-anal ultrasound 
and defaecography
SNS 
(after failure of BF, 
fiber, anti-motility 
agents) 12 months)
At a median follow-up of 
19.5 months, there were 
significant improvements 
in CCF-FI and in the LARS 
Scores (p=0.001) 
Drop out: none
Continues
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Table 2 
Continued
Author, year 
of publication, 
country
Aim Study design Sample Instrument Intervention/
description
Results 
Mege et al. 
2017 [22]
France
To analyze the 
effectiveness 
of SNS on poor 
functional results 
and on the QOL, 
after different 
colorectal 
resections.
Retrospective
Follow up: 
18 (3.5-91) 
months
Method: convenience
N: 16
Age: average 53 
Gender: M 43.8% (7/11), 
F 56.2% (9/16) 
Inclusion criteria: surgi-
cal treatment for rectal 
cancer or other diseases, 
unresponsive to con-
servative therapy (i.e. 
medications influencing 
stool consistency, pelvic 
floor rehabilitation and 
biofeedback) 
Surgical procedure: TP 
44% (7/16), LAR with 
TME 37% (6/16), LE 9% 
(3/16) 
Anastomosis type: IPAA 
44% (7/16), CA 37% 
(6/16) CR 19% (3/16) 
Temporary stoma: 81.2% 
(13/16)
Perioperative treatment: 
preoperative 25% (4/16) 
and postoperative CT 
12.5% (2/16)
LARS score 
(Emmertsen and 
Laurberg 2012)
CCF-FI (Jorge and 
Wexner 1993).
FIQL score 
(Rockwood et al. 
2000).
Endo-anal 
ultrasonography 
or pelvic Magnetic 
Resonance 
SNS
(ND)
In PC patient 
fecal urgency had 
improvement from 5 to 
0 (p=0.02) and bowel 
frequency from 11 to 5 
(p=0.004); FI from 4 to 1.8 
(p=0.03) 
In CA and CR 
anastomosis bowel 
frequency decreased 
from 10 to 2 (p=0.04), FI 
from 5 to 0.6 (p=0.02) 
while bowel urgency 
from 2 a 4.8 (p=0.86)
FIQL significantly 
improved 
Drop out: 2/16
Vigorita et al. 
2017 [24]
Spain
To evaluate the 
effectiveness of 
treatment with 
PTNS in LARS 
and to identify 
predictors of the 
outcome 
Prospective 
Follow up: 6 
week
Method: convenience
N: 10
Age: average 62 years
Gender: M 60% (6/10), F 
40% (4/10) 
Inclusion criteria: 
patients > 18 years 
old, surgical treatment 
for rectal cancer with 
LARS, unresponsive to 
conservative therapy 
(i.e. medications, fiber 
and biofeedback) 
Surgical procedure: LAR
Anastomosis type: ND
Perioperative treatment: 
CT 80% (8/10). 
Preoperative 50% (5/10) 
and postoperative RT
LARS score 
(Emmertsen and 
Laurberg 2012)
CCF-FI (Jorge and 
Wexner 1993)
FIQL score 
(Rockwood et al. 
2000)
Bowel diary
Endo-anal ultrasound 
and
anal manometry
PTNS 
(All patients had 2 
PTNS sessions per 
week - 30 min for 
6 weeks. Therefore 
patient with an 
improvement had 
second phase of 
PTNS)
LARS Score improvement 
has observed in 50% 
of patients with total 
resolution of LARS in 20% 
(2/10)
FI decreased in 70% 
(7/10) of the patients. 
The median Wexner 
score decreased from 14 
(IQR 10.75–18.5) to 10 
(IQR 6.5–18) after treat-
ment (p = 0.034) 
A significant improve-
ment in FIQL score in 
lifestyle, depression, and 
daily defecation urgency 
(p=0.05). 
Drop out: 3/10
Only seven patients 
(70%) responded posi-
tively after the first phase 
and received the second 
phase of treatment. 
After the second phase, 
three patients with major 
LARS symptoms became 
classified as minor LARS 
and two patients with 
minor LARS had resolu-
tion of the syndrome. 
Two patients did not 
show improvement in 
LARSS; however, they 
demonstrated an im-
provement in defecation 
diary and FIQL  Of the 
three patients who did 
not respond, two were 
from the major LARS 
group and one from the 
minor LARS group
Continues
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one used the CCF-FI [25] and bowel diary to evalu-
ate fecal incontinence and bowel movement; another 
[23] adopted the St Marks score [27] for fecal inconti-
nence assessment, while the other studies adopted the 
three axial perineal evaluation (TAPE) score [28, 29] 
(comprehensive of the obstructed defecation syndrome 
(ODS) score [30], the International Consultation on 
Incontinence Questionnaire-Short Form (ICIQ-SF) 
score [31], the Pelvic Organ Prolapse/Urinary Incon-
tinence Sexual Questionnaire (PISQIR) (IUGA-Re-
vised) [32], the International Index of Erectile Function 
(IIEF-5) Questionnaire (SHIM) [33], the Premature 
Ejaculation Diagnostic Tool (PEDT) score [34], and the 
Baden-Walker score [35] to measure obstructed def-
ecation, urinary incontinence, sexual dysfunctions, and 
genital prolapse. Urinary retention was scored accord-
ing to the volume of urine retention, if present (score 0 
when absent, 1 if > 50 ml, 2 if between 50-100 ml, and 
3 if > 100 ml of urine) and FI with the anal manometry 
for pressure assessment [23]. Follow up occurred from 
6 weeks [24] to 6 months [23].
Patients reported a significant improvement in fecal 
and urinary incontinence; obstructive defecation im-
proved in only three patients, and because the sample 
was not sexually active, sexual function was not assessed 
[23]. There were no significant changes in the FIQL 
and in anal pressure after PTNS [23]. In one study 
[24], all patients underwent PTNS in the first phase 
of the study; however, only those who experienced an 
improvement in incontinence (70%) were included in 
the second phase, and three patients showed no LARS 
improvements. In this study, QOL improved in lifestyle, 
depression, daily defecation, and urgency. 
DISCUSSION
Eighty percent of patients who undergo a low or very 
low rectal anterior resection with sphincter preservation 
will experience LARS [2], a syndrome that has adverse 
effects on patients’ QOL, in the postoperative period 
[2-4]. 
Currently, no indications of the best rehabilitative in-
terventions are available, and thus, we conducted this 
review to identify the treatments that reduce LARS 
symptoms best in patients who have undergone surgery. 
Methodological issues
The methodological quality of the studies selected 
differed significantly and all had a small sample size. 
Two used a retrospective design [20-22] that may 
have introduced a recall bias because patients must 
remember their symptoms. Moreover, the prospec-
tive studies used follow-up times that ranged from 6 
weeks [24] to 91 months [22]. The literature under-
scored the fact that LARS appears immediately after 
surgery, becomes more evident during the first several 
months, and stabilizes after approximately one to two 
years [7]; with this assumption, follow-up times up to 
two years should be appropriate. At the same time, 
we should consider the results of studies with shorter 
follow-up times with caution, because patients likely 
will experience further improvements in outcomes. 
Moreover, the studies with long follow-ups may be as-
sociated with a high percentage of drop out and the 
possibility of confounding variables biases, such as age 
or changes in clinical conditions [36], and the author 
can attribute treatment efficacy or failure to the level 
of the anastomosis from the anal verge (lower anas-
tomosis might have worst results) and preoperative 
radiotherapy [24]. Therefore, these factors’ potential 
roles must be explored in future studies, which also 
should include larger samples to assess the differences 
in treatment results with respect to the surgical proce-
dure and perioperative treatments.
 The studies’ inclusion criteria also differed greatly. 
One source of bias may be the inclusion of patient 
with a temporary stoma. The presence of a temporary 
Table 2 
Continued
F = female; M = male; ND = non described; FI = fecal incontinence; UI = urinary incontinence; QOL = quality of life.
Surgical procedure: LAR = low anterior resection; LARS = low anterior resection syndrome; LE = left hemicolectomy; PEC = percutaneous endoscopic cecostomy; 
PME = partial mesorectal excision; TME = total mesorectal excision;  TP = total proctolectomy. 
Anastomosis type: CA = coloanal anastomosis; CR = colorectal anastomosis; EtE = end-to-end anastomosis; HS = hand-sewn anastomosis; IPAA = ileal pouch-anal 
anastomosis; JP = j-pouch anastomosis; StE = side-to-end anastomosis.
Treatments: AE = anterograde enema; BF = biofeedback; CT = chemotherapy; PNE = percutaneous nerve evaluation; PTNS = percutaneous tibial nerve 
stimulation; RT = radiotherapy; SNS = Sacral Nerve Stimulation. 
Scales: 
Baden-Walker score ((Baden and Walker 1972): for genital prolapse assessment.
Cleveland Clinic Florida Fecal Incontinence (CCF-FI) scoring system or Wexner Fecal Incontinence Score (Jorge JM and Wexner SD 1993): to assess fecal incontinence. The 
range score from 0-8 (midle incontinence), 9-14 (moderate incontinence), 15-20 (severe incontinence).
Fecal Incontinence Quality of Life score (FIQL) (Rockwood et al. 2000): to assess fecal incontinence quality of life: divided in 4 dimensions (Depression, Embarrassment, 
Life Style and Coping). The score range from 1 (low quality of life) to 4 (good quality of life). 
Gastrointestinal Quality of Life Index (GIQLI) (Slimet al. 1999): to assess quality of life in physical status, emotions, social integration, and the effect of medical 
treatment. The score ranging from 0 to 144 (excellent). 
International Index of Erectile Function (IIEF-5) (Rosen et al. 1999): diagnostic tool for erectile dysfunction.
International Consultation on Incontinence Questionnaires Short Form (ICIQ-SF) (Tubaro et al. 2006): for assessment of urinary incontinence. 
Low Anterior Resection Syndrome score (LARS) (Emmertsen et al. 2012): to assess LARS syndrome. The range score was from 0 to 42: 0 to 20 (no LARS), 21 to 29 (minor 
LARS), and 30 to 42 (major LARS).
Obstructed Defecation Syndrome (ODS) (Altomare et al. 2008): to assess obstructed defecation. 
Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQIR) (Rogers et al. 2013): questionnaire for sexual dysfunction.
Premature Ejaculation Diagnostic Tool (PEDT) (Symond et al. 2017): for assessment sexual disfunction in man.
St. Mark’s score (Vaizey et al. 1999): to assess fecal incontinence. The score range from 0 (continence) to 24 (incontinence). 
Three Axial Perineal Evaluation score (TAPE) (Atlomare et al. 2017): to assess pelvic floor function evaluation (urinary, fecal and sexual) normal value 100% of 
hexagonal area. 
Urinary retention: was scored according to the volume of urine retention if present (score 0 when absent, 1 if >50 ml, 2 if between 50-100ml and 3 if > 100ml of 
urine).  
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ileostomy is a risk factor for bowel dysfunction follow-
ing surgery [37, 38] because prolonged inactivity of the 
pelvic floor and sphincter complex contributes to LARS 
[39-40].
The researchers used different instruments to assess 
LARS outcomes, QOL, and incontinence, and thus, 
the results of the studies are not comparable; more-
over, a meta-analysis cannot be conducted. Therefore, 
we should consider the outcomes evaluations with cau-
tion. In addition, the LARS score simply is a screen-
ing instrument [21] and does not consider urinary and 
sexual dysfunction, which are included as symptoms in 
LARS syndrome [41, 42]. With this assumption, LARS 
[18] scores always should be accompanied by the TAPE 
score [28, 29]. 
Treatments to reduce LARS symptoms 
We selected studies that included adult patients who 
underwent low rectum resection with sphincter preserva-
tion and with pre/post LARS evaluation. The treatments 
analyzed were the SNS [20-22] and PTNS [23, 24]. 
The patients recruited were treated first with con-
servative therapy, including constipating medications, 
physiotherapeutic pelvic floor exercises, and biofeed-
back, all of which have been demonstrated effective 
in improving FI, bowel movement [43-45], and QOL 
[43-45]. We need stronger evidence about conservative 
therapy’s efficacy and which outcomes it improves most 
effectively; these findings should indicate whether to 
submit patients for conservative therapy initially, and 
then, in cases of inefficacy, for other treatments.
Two studies [23, 24] considered PTNS treatment. 
One [23] concluded that it offers a moderate improve-
ment in LARS syndrome, but argued that it can be asso-
ciated with the time or the level of the anastomosis and 
preoperative treatment, while the other study [24] in-
cluded a sample of only 10 patients and considered only 
those who showed improvement after the first phase of 
PTNS in the outcome assessment. Among these, two 
demonstrated no improvement in the LARS score, but 
QOL and defecation habits did improve [24]. Future 
studies should investigate more thoroughly the roles the 
anastomosis level and type and preoperative treatment 
(chemotherapy and radiotherapy) play in the LARS re-
habilitation process. 
Three studies addressed SNS efficacy in improving 
LARS [20-22]. One found improvement in such FI and 
LARS symptoms as clustering and urgency. The sec-
ond [21] demonstrated that SNS is effective for LARS 
and FI, fragmentation, and urgency, but four patients, 
all with major LARS, had insufficient responses to the 
treatment. The final study [22] was multi-centric, but 
retrospective, with a small sample, and found improve-
ment in FI, LARS scores, stool frequency, and urgen-
cy in 86% of cases. In the outcome evaluation, these 
authors [20-22] also used manometry [20-22], colpo-
cysto-defecography [20-22], ultrasound of the anal 
sphincter [20-22], anorectal dyssynergy [22], sphincter 
electromyogram [22], and magnetic resonance [22], 
and not simply self-reports or medical records alone. 
However, there were no post treatment data on these 
evaluations.
It is difficult to judge which treatment is the best, be-
cause only two studies considered PTNS [23, 24] and 
only one [23] evaluated patient outcomes thoroughly 
and extensively. Moreover, the authors argued about 
moderate improvement [23] or excluded patients who 
did not improve during the first phase of the study 
from the second phase of PTNS [24]. Among the three 
studies that evaluated SNS [20-22], two demonstrated 
improved outcomes, although they were retrospective 
[2,22]. Our conclusion seems to confirm Ramage et al. 
finding, in which the authors reported a significant im-
provement of LARS symptoms in 74% of patients after 
SNS. However, this technique’s high cost also must be 
considered [46]. 
This review has several limitations. We consulted 
only certain databases and included only those studies 
with abstracts available. Therefore, despite the system-
atic approach we used to identify studies, these con-
ditions may have excluded some publications. Lastly, 
by including only studies with pre and post treatment 
LARS score evaluations, we may have excluded from 
our review studies that reported potentially valid treat-
ments.
Implications for practice and further research
Future studies must be multi-centric RCTs with larg-
er samples of patients who have failed to respond to 
conservative therapy. Further, great attention should 
be given to the patient inclusion criteria. Because the 
LARS etiology is multifactorial [47, 48], we must con-
sider patient groups that represent every surgical proce-
dure and perioperative treatment.
Moreover, the follow up time should be approximate-
ly two years, because LARS symptoms have stabilized 
by that time [7]. 
In clinical practice patients should evaluate with the 
LARS [18] and TAPE scores [28, 29] in pre and post 
treatment, and the FIQL [26] should be considered in 
the QOL assessment. Only two studies [32, 33] consid-
er the urinary and sexual dysfunction which are includ-
ed as symptoms in LARS syndrome [41, 42]. Physician 
should take into consideration any patient problem and 
should include in their interventions also the caregiv-
ers. In addition, our findings highlight the importance 
to include in education programs the best rehabilitation 
strategies for the patient affected of LARS.
CONCLUSION
Most patients who undergo a low or very low rectal 
anterior resection experience LARS postoperatively, a 
syndrome that has significant adverse effects on their 
satisfaction and QOL. From our review, SNS seems to 
be the most effective treatment for LARS symptoms 
and is less expensive than is PTNS; however, PTNS is a 
minimally invasive procedure [23]. 
Future research must be implemented with higher 
quality studies and with pre-post treatment assessment 
with LARS scores. This will allow us to develop the 
most effective intervention protocol, with the goal of 
identifying the least invasive and most effective treat-
ment for LARS. 
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